NCT02784444View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

PHASE2CompletedINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

September 14, 2016

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Non-alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

MSDC-0602K

MSDC-0602K capsules

DRUG

Placebo

Placebo capsules

Trial Locations (43)

10018

New York

23249

Richmond

27834

Greenville

28304

Fayetteville

28677

Statesville

30060

Marietta

32610

Gainesville

33016

Hialeah

Miami Lakes

33414

Wellington

34211

Lakewood Rch

34452

Inverness

37076

Hermitage

38138

Germantown

39232

Flowood

46202

Indianapolis

70112

New Orleans

70115

New Orleans

71220

Bastrop

71291

West Monroe

75203

Dallas

76012

Arlington

77030

Houston

78215

San Antonio

78233

Live Oak

78234

Fort Sam Houston

78265

San Antonio

78746

Rollingwood

80113

Englewood

85224

Chandler

85712

Tucson

90036

Los Angeles

90057

Los Angeles

90255

Huntington Park

91910

Chula Vista

91942

La Mesa

92064

Poway

92103

San Diego

92377

Rialto

92844

Garden Grove

93701

Fresno

112301

Brooklyn

02905

Providence

Sponsors
All Listed Sponsors
collaborator

Chiltern International Inc.

INDUSTRY

lead

Cirius Therapeutics, Inc.

INDUSTRY